Clinuvel Pharmaceuticals Ltd

ASX:CUV (Australia)   Ordinary Shares
A$ 13.92 (+1.75%) Mar 1
23.51
P/B:
3.79
Market Cap:
A$ 689.69M ($ 450.70M)
Enterprise V:
A$ 516.31M ($ 337.40M)
Volume:
148.76K
Avg Vol (2M):
92.17K
Also Trade In:
Volume:
148.76K
Avg Vol (2M):
92.17K

Business Description

Description
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
Name Current Vs Industry Vs History
Cash-To-Debt 163.19
Equity-to-Asset 0.84
Debt-to-Equity 0.01
Debt-to-EBITDA 0.02
Interest Coverage 10.95
Piotroski F-Score 7/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 16.17
Distress
Grey
Safe
Beneish M-Score -2.33
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 37.79
9-Day RSI 36.34
14-Day RSI 37.51
6-1 Month Momentum % -16.1
12-1 Month Momentum % -19.9

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.86
Quick Ratio 6.43
Cash Ratio 5.94
Days Inventory 408.56
Days Sales Outstanding 66.73
Days Payable 208.45

Financials

ASX:CUV's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Clinuvel Pharmaceuticals Ltd Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$) 81.223
EPS (TTM) (A$) 0.582
Beta 1.36
Volatility % 37.47
14-Day RSI 37.51
14-Day ATR (A$) 0.62306
20-Day SMA (A$) 15.2585
12-1 Month Momentum % -19.9
52-Week Range (A$) 13.29 - 21.53
Shares Outstanding (Mil) 49.55

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 7
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Clinuvel Pharmaceuticals Ltd Filings

Filing Date Document Date Form
No Filing Data

Clinuvel Pharmaceuticals Ltd Stock Events

Financials Calendars
Event Date Price(A$)
No Event Data

Clinuvel Pharmaceuticals Ltd Frequently Asked Questions

What is Clinuvel Pharmaceuticals Ltd(ASX:CUV)'s stock price today?
The current price of ASX:CUV is A$13.92. The 52 week high of ASX:CUV is A$21.53 and 52 week low is A$13.29.
When is next earnings date of Clinuvel Pharmaceuticals Ltd(ASX:CUV)?
The next earnings date of Clinuvel Pharmaceuticals Ltd(ASX:CUV) is .
Does Clinuvel Pharmaceuticals Ltd(ASX:CUV) pay dividends? If so, how much?
The  Dividend Yield %  of Clinuvel Pharmaceuticals Ltd(ASX:CUV) is 0.37% (As of Today), Highest Dividend Payout Ratio of Clinuvel Pharmaceuticals Ltd(ASX:CUV) was 0.09. The lowest was 0.05. And the median was 0.06. The  Forward Dividend Yield % of Clinuvel Pharmaceuticals Ltd(ASX:CUV) is 0.37%. For more information regarding to dividend, please check our Dividend Page.

Press Release

Subject Date
No Press Release